Publications en collaboration avec des chercheurs de University of Texas MD Anderson Cancer Center (49)

2024

  1. Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes

    Nature Communications, Vol. 15, Núm. 1

  2. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia

    American Journal of Hematology, Vol. 99, Núm. 4, pp. 586-595

2023

  1. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

    The Lancet, Vol. 401, Núm. 10373, pp. 269-280

  2. The International Consensus Classification of myelodysplastic syndromes and related entities

    Virchows Archiv, Vol. 482, Núm. 1, pp. 39-51

  3. Unmet Clinical Needs and Management Recommendations for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Consensus-based Position Paper from an Ad Hoc International Expert Panel

    HemaSphere, Vol. 7, Núm. 3, pp. E841

2022

  1. Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781

  2. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

    Blood, Vol. 140, Núm. 11, pp. 1200-1228

  3. Nuclear Vav3 is required for polycomb repression complex-1 activity in B-cell lymphoblastic leukemogenesis

    Nature Communications, Vol. 13, Núm. 1

2021

  1. Flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: International guidelines for assay characteristics

    Cytometry Part B - Clinical Cytometry, Vol. 100, Núm. 2, pp. 142-155

  2. International guidelines for the flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: Assay development/optimization, validation, and ongoing quality monitors

    Cytometry Part B - Clinical Cytometry, Vol. 100, Núm. 2, pp. 156-182

  3. Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions

    HemaSphere, Vol. 5, Núm. 3, pp. E536

  4. Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 2, pp. 97-105

2019

  1. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    The Lancet, Vol. 393, Núm. 10168, pp. 229-240

  2. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

    European Journal of Immunology, Vol. 49, Núm. 10, pp. 1457-1973

  3. YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib

    American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899

2018

  1. Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: Results from the open-label, multicenter, phase II DAWN study

    Journal of Clinical Oncology, Vol. 36, Núm. 23, pp. 2405-2412

  2. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204

  3. Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia

    Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73

2017

  1. Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents

    American Journal of Hematology, Vol. 92, Núm. 4, pp. 351-358

2016

  1. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition

    Cytometry Part B - Clinical Cytometry, Vol. 90, Núm. 1, pp. 26-30